|
A word from the Editor,
Stuart Maddin Welcome to the Skin Therapy Letter. As we look forward
to future issues, we will be bringing you new information from authoritative sources
concerning the treatment of patients, including material on new and existing drugs that is
practical, balanced, and has immediate clinical relevance whether you're a clinical
practitioner or hospital-based dermatologist.
New formulations, drug interactions, adverse effects, and the latest information on new
uses for old drugs will all be covered. We will keep you abreast of treatment advances
reported at major dermatology meetings, symposia, and international congresses, and will
also draw from years of clinical experience, treatment protocols from centres recognized
for their expertise, respected journals, and clinical trials worldwide.
The opinions expressed will be balanced and clinically relevant, reflecting the
Editor's own experience and extensive drug reporting dating back to the 1960s, and the
strong contributions of our international Editorial Advisory Board.
We look forward to receiving your feedback.
|
|
